Quinolones et fluoroquinolones : des décennies de développement et d'utilisation : Le point sur les molécules vétérinaires : partie 2, le regard du vétérinaire
Muylaert, Adeline ; Université de Liège - ULiège > Département des maladies infectieuses et parasitaires (DMI) > Bactériologie et pathologie des maladies bactériennes
Mainil, Jacques ; Université de Liège - ULiège > Département des maladies infectieuses et parasitaires (DMI) > Bactériologie et pathologie des maladies bactériennes
Language :
English
Title :
Quinolones et fluoroquinolones : des décennies de développement et d'utilisation : Le point sur les molécules vétérinaires : partie 2, le regard du vétérinaire
AGENCE FEDERALE DES MEDICAMENTS ET DES PRODUITS DE SANTE Notice et résumé des caractéristiques du produit. [en ligne] (sans date) Adresse URL: http://195.130.154.23/fagg/(S(nusafv55fl14fzqdopvm0z45))/Fagg/FaggCompendium.aspx?compendiumType=V, consulté le 20/06/2011.
BARTON T.D., FISHMAN N.O., WEINER M.G., LAROSA L.A., LAUTENBACH E. High rate of coadministration of di-or tri-valent cation-containing compounds with oral fluoroquinolones: risk factors and potential implications. Infect. Control Hosp. Epidemiol., 2005, 26, 93-99.
BLONDEAU J.M., BORSOS S., BLONDEAU L.D., BLONDEAU B.J. In vitro killing of Escherichia coli, Staphylococcus pseudintermedius and Pseudomonas aeruginosa by enrofloxacin in combination with its active metabolite ciprofloxacin using clinically relevant drug concentrations in the dog and cat. Vet. Microbiol., 2012, 155, 284-290.
BOERLIN P., REID-SMITH R.J. Antimicrobial resistance: its emergence and transmission. Anim. Health Res. Rev., 2008, 9, 115-126.
BOLON M.K. The newer fluoroquinolones. Infect. Dis. Clin. N. Am., 2009, 23, 1027-1051.
BROWN S.A. Fluoroquinolones in animal health. J. Vet. Pharmacol. Ther., 1996, 19, 1-14.
BRYSKIER A. Fluoroquinolones. In: Bryskier A. (Ed.), Antimicrobial agents, antibacterials and antifungals. ASM Press: Washington, 2005, 668-788.
BURKHARDT J.E., HILL M.A., CARLTON W.W., KESTERSON J.W. Histologic and histochemical changes in articular cartilages of immature beagle dogs dosed with difloxacin, a fluoroquinolone. Vet. Pathol., 1990, 27, 162-170.
BURKHARDT J.E., HILL M.A., CARLTON W.W. Morphologic and biochemical changes in articular cartilages of immature beagle dogs dosed with difloxacin. Toxicol. Pathol., 1992a, 20, 246-252.
BURKHARDT J.E., HILL M.A., TUREK J.J., CARLTON W.W. Ultrastructural changes in articular cartilages of immature beagle dogs dosed with difloxacin, a fluoroquinolone. Vet. Pathol., 1992b, 29, 230-238
BURKHARDT J.E., WALTERSPIEL J.N., SCHAAD U.B. Quinolone arthropathy in animals versus children. Clin. Infect. Dis., 1997, 25, 1196-1204.
CENTRE BELGE D'IN- FORMATION PHARMA-CO-THERAPEUTIQUE Répertoire commenté des médicaments à usage vétérinaire (2011a). [en ligne] Adresse URL: http://www.cbip-vet.be/fr/texts/FAMOOOL1JL2o.php, consulté le 25/10/2011.
CENTRE BELGE D'IN- FORM AT ION PHARMA- COTHERAPEUTIQUE Système de la cascade. (2011b). [en ligne] Adresse URL: http://www.cbip-vet.be/fr/texts/frcascade.php, consulté le 20/06/2011.
COHEN K.A., LAUTENBACH E., WEINER M.G., SYNNESTVEDT M., GASINK L.B. Coadministration of oral levofloxacin with agents that impair absorption: impact on antibiotic resistance. Infect. Control Hosp. Epidemiol., 2008, 29, 975-977.
COULET M., VAN BORSSUM WAALKES M., LEEUWENKAMP O.R., COX P., LOHUIS J. Pharmacokinetics of ibafloxacin following intravenous and oral administration to healthy Beagle dogs. J. Vet. Pharmacol. Ther., 2002a, 25, 89-97.
COULET M., VAN BORSSUM WAALKES M., COX P., LOHUIS J. In vitro and in vivo pharmacodynamic properties of the fluoroquinolone ibafloxacin. J. Vet. Pharmacol. Ther., 2002b, 25, 401-411.
CRAIG W.A., ANDES D.R. Pharmacodynamics of quinolone antimicrobial agents. In: Hooper D.C., Rubinstein E. (Eds), Quinolone antimicrobial agents. 3rd edition. ASM Press: Washington, 2003, 147-155.
DOMAGALA J.M., HAGEN S.E. Structure-activity relationships of the quinolone antibacterials in the new millennium: some things change and some do not. In: Hooper D.C., Rubinstein E. (Eds), Quinolone Antimicrobial Agents 3rd edition. ASM Press: Washington, 2003, 3-18.
EGERBACHER M., EDINGER J., TSCHULENK W. Effects of enrofloxacin and ciprofloxacin hydrochloride on canine and equine chondrocytes in culture. Am. J. Vet. Res., 2001, 62, 704-708.
ELLIS R.J., MAYO M.S., BODENSTEINER D.M. Ciprofloxacin-warfarin coagulopathy: a case series. Am. J. Hematol., 2000, 63, 28-31.
FOLIA VETERINARIA Quels médicaments peuvent être prescrits et délivrés en médecine vétérinaire ? Le point sur l'application du "système de la cascade" et l'importation des médicaments. (2003) [en ligne] Adresse URL: http://www.bcfi-vet.be/fr/frinfos/frfolia/03FVF3c.pdf, consulté le 20/06/2011.
FOLIA VETERINARIA Le système de la cascade pour le médecin vétérinaire (arbre décisionnel). (2004) [en ligne] Adresse URL: http://www.bcfi-vet.be/fr/frinfos/frfolia/04FVF3b.pdf, consulté le 20/06/2011.
FORD M.M., DUBIELZIG R.R., GIULIANO E.A., MOORE C.P., NARFSTROM K.L. Ocular and systemic manifestations after oral administration of a high dose of enrofloxacin in cats. Am. J. Vet. Res., 2007, 68, 190-202.
GAYNES, R., RIMLAND D., KILLUM E., LOWERY H.K., JOHNSON T.M., 2ND, KILLGORE G., TENOVER F.C. Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Clin. Infect. Dis., 2004, 38, 640-645.
GELATT K.N., VAN DER WOERDT A., KETRING K.L., ANDREW S.E., BROOKS D.E., BIROS D.J., DENIS H.M., CUTLER T.J. Enrofloxacin-associated retinal degeneration in cats. Vet. Ophthalmol., 2001, 4, 99-106.
GERDING D.N. Clindamycin, cephalosporins, fluoroquinolones, and Clostridium difficile -associated diarrhea: this is an antimicrobial resistance problem. Clin. Infect. Dis., 2004, 38, 646-648.
GROBBEL M., LUBKE-BECKER A., WIELER L.H., FROYMAN R., FRIEDERICHS S., FILIOS S. Comparative quantification of the in vitro activity of veterinary fluoroquinolones. Vet. Microbiol., 2007, 124, 73-81.
IANNINI P., MANDELL L., PATOU G., SHEAR N. Cutaneous adverse events and gemifloxacin: observations from the clinical trial program. J. Chemother., 2006, 18, 3-11.
LABBE A.C., POIRIER L., MACCANNELL D., LOUIE T., SAVOIE M., BELIVEAU C., LAVERDIERE M., PEPIN J. Clostridium difficile infections in a Canadian tertiary care hospital before and during a regional epidemic associated with the BI/NAP1/027 strain. Antimicrob. Agents Chemother., 2008, 52, 3180-3187.
LIPSKY B.A., BAKER C.A. Fluoroquinolone toxicity profiles: a review focusing on newer agents. Clin. Infect. Dis., 1999, 28, 352-364.
LOO V.G., POIRIER L., MILLER M.A., OUGHTON M., LIBMAN M.D., MICHAUD S., BOURGAULT A.M., NGUYEN T., FRENETTE C., KELLY M., VIBIEN A., BRASSARD P., FENN S., DEWAR K., HUDSON T.J., HORN R., RENE P., MONCZAK Y., DASCAL A. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N. Engl. J. Med., 2005, 353, 2442-2449.
MARTINEZ M., MCDERMOTT P., WALKER R. Pharmacology of the fluoroquinolones: a perspective for the use in domestic animals. Vet. J., 2006, 172, 10-28.
Mc CUSKER M.E., HARRIS A.D., PERENCEV ICH E., ROGHMANN M.C. Fluoroquinolone use and Clostridium difficile-associated diarrhea. Emerg. Infect. Dis., 2003, 9, 730-733.
McFARLAND L.V., CLARRIDGE J.E., BENEDA H.W., RAUGI G.J. Fluoroquinolone use and risk factors for Clostridium difficile-associated disease within a Veterans Administration health care system. Clin. Infect. Dis., 2007, 45, 1141-1151.
McKELLAR Q.A., SANCHEZ BRUNI S.F., JONES D.G. Pharmacokinetic/pharmacodynamic relationships of antimicrobial drugs used in veterinary medicine. J. Vet. Pharmacol. Ther., 2004, 27, 503-514.
MEHLHORN A.J., BROWN D.A. Safety concerns with fluoroquinolones. Ann. Pharmacother., 2007, 41, 1859-1866.
NEU H.C. Synergy and antagonism of combinations with quinolones. Eur. J. Clin. Microbiol. Infect. Dis., 1991, 10, 255-261.
OWENS R.C., JR., NOLIN T.D. Antimicrobial-associated QT interval prolongation: pointes of interest. Clin. Infect. Dis., 2006, 43, 1603-1611.
PARK-WYLLIE L.Y., JUURLINK D.N., KOPP A., SHAH B.R., STUKEL T.A., STUMPO C., DRESSER L., LOW D.E., MAMDANI M.M. Outpatient gatifloxacin therapy and dysglycemia in older adults. N. Engl. J. Med., 2006, 354, 1352-1361.
PEPIN J., SAHEB N., COULOMBE M.A., ALARY M.E., CORRIVEAU M.P., AUTHIER S., LEBLANC M., RIVARD G., BETTEZ M., PRIMEAU V., NGUYEN M., JACOB C.E., LANTHIER L. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin. Infect. Dis., 2005, 41, 1254-1260.
QAQISH R., POLK R. Drug-drug interactions. In: Hooper D.C., Rubinstein, E. (Eds), Quinolone antimicrobial agents. 3rd edition. ASM Press: Washington, 2003, 133-146.
RANDINITIS E.J., ALVEY C.W., KOUP J.R., RAUSCH G., ABEL R., BRON N.J., HOUNSLOW N.J., VASSOS A.B., SEDMAN, A.J. Drug interactions with clinafloxacin. Antimicrob. Agents Chemother., 2001, 45, 2543-2552.
RAZAVI B., APISARNTHANARAK A., MUNDY L.M. Clostridium difficile: emergence of hypervirulence and fluoroquinolone resistance. Infection, 2007, 35, 300-307.
SATOH Y., SUGIYAMA A., CHIBA K., TAMURA K., HASHIMOTO K. QT-prolonging effects of sparfloxacin, a fluoroquinolone antibiotic, assessed in the in vivo canine model with monophasic action potential monitoring. J. Cardiovasc. Pharmacol., 2000, 36, 510-515.
SPRENG M., DELEFORGE J., THOMAS V., BOISRAME B., DRUGEON H. Antibacterial activity of marbofloxacin: a new fluoroquinolone for veterinary use against canine and feline isolates. J. Vet. Pharmacol. Ther., 1995, 18, 284-289.
STAHLMANN R., LODE H. Toxicity of quinolones. Drugs, 1999, 58: Suppl 2, 37-42.
TAKIZAWA T., HASIMOTO K., ITOH N., YAMASHITA S., OWEN K. A comparative study of the repeat dose toxicity of grepafloxacin and a number of other fluoroquinolones in rats. Hum. Exp. Toxicol., 1999, 18, 38-45.
TEMPLE M.E., NAHATA M.C. Interaction between ciprofloxacin and rifampin. Ann. Pharmacother., 1999, 33, 868-870.
VAN BAMBEKE F., MICHOT J.M., VAN ELDERE J., TULKENS P.M. Quinolones in 2005: an update. Clin. Microbiol. Infect., 2005, 11, 256-280.
VAN DER LINDEN P.D., STURKENBOOM M.C., HERINGS R.M., LEUFKENS H.M., ROWLANDS S., STRICKER B.H. Increased risk of achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids. Arch. Intern. Med., 2003, 163, 1801-1807.
VON KEUTZ E., SCHLUTER G. Preclinical safety evaluation of moxifloxacin, a novel fluoroquinolone. J. Antimicrob. Chemother., 1999, 43: Suppl B, 91-100.
WIEBE V., HAMILTON P. Fluoroquinolone-induced retinal degeneration in cats. J. Am. Vet. Med. Assoc., 2002, 221, 1568-1571.
WISPELWEY B. Clinical implications of pharmacokinetics and pharmacodynamics of fluoroquinolones. Clin. Infect. Dis., 2005, 41: Suppl 2, S127-135.
YIP C., LOEB M., SALAMA S., MOSS L., OLDE J. Quinolone use as a risk factor for nosocomial Clostridium difficile-associated diarrhea. Infect. Control Hosp. Epidemiol., 2001, 22, 572-575.
YOON J.H., BROOKS R.L., JR. KHAN A., PAN H., BRYAN J., ZHANG J., BUDSBERG S.C., MUELLER P.O., HALPER J. The effect of enrofloxacin on cell proliferation and proteoglycans in horse tendon cells. Cell. Biol. Toxicol., 2004, 20, 41-54.